Results 71 to 80 of about 85,599,608 (253)

Spatiotemporally Controlled Sequential Chemo‐Immunotherapy Activates Pyroptosis for Robust Anti‐Tumor Immunotherapy

Advanced Science, EarlyView.
A glutathione and ultrasound dual‐responsive cerasome achieves sequential co‐delivery of gemcitabine and BMS1166 in tumors. Chemotherapy priming followed by on‐demand PD‐L1 blockade synergistically amplifies anti‐tumor immunity, inhibiting primary tumor growth, distant metastasis and inducing durable immune memory.
Suhui Sun, Ruiqi Wu, Qingshuang Tang, Yunli Xu, Wanrui Shi, Mengxin Wang, Haonan Wang, Yan Luo, Cheng Ma, Xiaolong Liang   +9 more
wiley   +1 more source

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms

Frontiers in Pharmacology, 2017
Diabetes mellitus has been demonstrated to be closely associated with osteoporosis. Accordingly, hypoglycemic therapy is considered effective in treating metabolic bone disease.
Yinqiu Yang, Chenhe Zhao, Jing Liang, Mingxiang Yu, Xinhua Qu   +4 more
doaj   +1 more source

Asymmetric Structure‐Driven Functional Synergy: A Multistimuli‐Activated Janus Nanomotor for Self‐Amplifying NO Cascade Therapy

Advanced Science, EarlyView.
The Janus nanomotors leverage an “asymmetric structure‐driven functional synergy” strategy to orchestrate spatiotemporally coordinated catalytic functions, in situ self‐amplifying NO generation, and deep tumor penetration, thereby enabling controllable, sustained, and uniform NO generation within the tumor microenvironment.
Chengcheng Li, Yu Zhang, Yu Chen, Lingyun He, Xian Shen, Weijian Sun, Hongbo Zhang   +6 more
wiley   +1 more source

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundPredictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus.
Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Daiju Fukuda, Hotimah Masdan Salim, Masayoshi Ishida, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Toshio Matsumoto, Masataka Sata   +15 more
doaj   +1 more source

Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

, 2011
International audienceInhibition of dipeptidyl peptidase-4 (DPP-4) activity improves glucose homeostasis through a mode of action related to the stabilization of the active forms of DPP-4-sensitive hormones such as the incretins that enhance glucose ...
Pierre Cattan, Thierry Sulpice, Myriam Masseboeuf, Jens J. Holst, Waget, Aurélie, Holst, Jens Juul, Drucker, Daniel J, Magnan, Christophe, Rémy Burcelin, Sulpice, Thierry, Mélis Karaca, Adriano Maida, Castel, Julien, Maida, Adriano, Burcelin, Rémy, Mattieu Armanet, Cattan, Pierre, Julien Castel, Holst, Jens J, Celine Garret, Masseboeuf, Myriam, Armanet, Mattieu, Payros, Gaëlle, Cabou, Cendrine, Christophe Magnan, Cendrine Cabou, Aurélie Waget, Gaëlle Payros, Daniel J. Drucker, Garret, Celine, Karaca, Mélis   +30 more
core   +1 more source

Loss of Intestinal MSTN Promotes GLP‐1 Secretion Through SGLT1 Palmitoylation

Advanced Science, EarlyView.
Intestinal MSTN deficiency enhances glucose‐stimulated GLP‐1 secretion and glucose tolerance in high‐fat diet‐fed mice. Mechanistically, loss of MSTN promotes YY1‐associated ZDHHC20 expression, increasing SGLT1 S‐palmitoylation at Cys301 and its plasma membrane localization in L cells.
Sheng‐Zhong Han, Shuang‐Yan Chang, Zhaobo Luo, Ke Sun, Biaohu Quan, Yanqiu Lv, Zhouyan Li, Xinyue Liu, Sitong Lv, Meifu Xuan, Xiaoyufan Xu, Xue Fang, Hang Chang, Rihuan Zhang, Xi‐Jun Yin, Lin‐Hu Quan, Jin‐Dan Kang   +16 more
wiley   +1 more source

Funnel plot for mean difference (MD) in the change in HbA1c (DPP-4 inhibitor vs. placebo or no treatment).

, 2014
Funnel plot for mean difference (MD) in the change in HbA1c (DPP-4 inhibitor vs. placebo or no treatment).
Dongsheng Cheng (652883), Xiaoxia Wang (14667), Junhui Li (304434), Yumei Liu (286628), Yuqiang Chen (652884), Niansong Wang (304438), Yang Fei (504329)   +6 more
core   +1 more source

Aortic valve disease: Novel animal models for advancing our understanding of the underlying mechanisms

Animal Models and Experimental Medicine, EarlyView.
Due to the complex pathophysiology of aortic valve disease (AVD) and the resulting lack of effective pharmacotherapy, existing animal models are valuable research tools, but each has its own strengths and limitations. This review systematically surveys the major AVD models, compares their induction methods, pathological features, advantages and ...
Liya Hou, Xue Liu, Wangxing Hu, Xianbao Liu, Wei Zhu   +4 more
wiley   +1 more source

Time course of the recovery of DPP-4 activity following dissociation of trelagliptin from the preformed DPP-4-inhibitor complex.

, 2016
A preformed enzyme-inhibitor complex (where [DPP-4] = 50 nmol/L and trelagliptin concentration is as shown in the plot) was diluted 50-fold into a solution containing 2 mmol/L GP-pNA substrate (approximately 17x Km).
Yoshinobu Kinugawa (3165234), Nobuhiro Nishigaki (2134261), Akiyoshi Tani (2231677), Hiroki Sano (2962497), Koji Takeuchi (469159), Charles E. Grimshaw (3165231), Andy Jennings (2235538), Hikaru Ueno (3165237), Takuo Kosaka (2231683), Lihong Shi (481066), Emiko Koumura (3165240), Ruhi Kamran (1786588)   +11 more
core   +1 more source

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

, 2013
Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-
Kishimoto M
core